This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||EYEG / Eyegate Pharmaceuticals Inc. (30233M107)|
|President and CEO||FROM STEPHEN|
|Institutional Shares||17,292,859 - 39.81%|
|Common Shares Outstanding||43,439,130 shares (as of 2018-06-30)|
|Institutional Value||$ 9,178,000 USD|
EYEGW / Eyegate Pharmaceuticals Inc. Warrants|
Institutional Stock Ownership and Shareholders()
Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) has 21 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17,292,859 shares.
Largest shareholders include
Armistice Capital, Llc, Vanguard Group Inc, Essex Investment Management Co Llc, Barclays Plc, Us Bancorp \de\, IFP Advisors, Inc, Citadel Advisors Llc, Credit Suisse Ag/, Wedbush Securities Inc, and Raymond James Financial Services Advisors, Inc..
Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|IFP Advisors, Inc||26,800||26,800||0.00||10||14||40.00|
|CITADEL ADVISORS LLC||56,628||25,851||-54.35||22||14||-36.36|
|ESSEX INVESTMENT MANAGEMENT CO LLC||73,492||39|
|CREDIT SUISSE AG/||26,500||22,000||-16.98||10||12||20.00|
|Holistic Financial Partners||1,900||0||-100.00||1||0||-100.00|
|ROYAL BANK OF CANADA||12,356||12,355||-0.01||5||7||40.00|
|WELLS FARGO & COMPANY/MN||100||100||0.00||0||0|
|VANGUARD GROUP INC||73,949||114,949||55.44||28||61||117.86|
|TWO SIGMA SECURITIES, LLC||12,603||0||-100.00||5||0||-100.00|
|Vantage Investment Advisors, LLC||6,500||6,500||0.00||2||3||50.00|
|Raymond James Financial Services Advisors, Inc.||15,000||8|
|BlackRock Fund Advisors||10,254||10,352||0.96||18||17||-5.56|
|Bank of New York Mellon Corp||28,835||0||-100.00||11||0||-100.00|
|ACADIAN ASSET MANAGEMENT LLC||16,671||0||-100.00||6||0||-100.00|
|BlackRock Investment Management, LLC||728||728||0.00||1||1||0.00|
|US BANCORP \DE\||40,650||40,650||0.00||15||22||46.67|
|WEDBUSH SECURITIES INC||20,000||20,000||0.00||8||11||37.50|
|NORTHERN TRUST CORP||14,553||14,553||0.00||6||8||33.33|
|LADENBURG THALMANN FINANCIAL SERVICES INC||9,226||9,226||0.00||4||4||0.00|
|UBS Group AG||1,537||14,316||831.42||1||8||700.00|
|ARMISTICE CAPITAL, LLC||1,192,000||16,802,500||1,309.61||453||8,905||1,865.78|
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...
Related News Stories
Discussion: Biohaven Pharmaceutical Holding Company (BHVN) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo. (10-2)
Shares of fallen nearly 70% year to date but appear to be ready to fill the gap back to the psychologically important $1 level. (22-3)
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis. (143-3)
April 13, 2018: Here are four stocks trading with heavy volume among 52 equities making new 52-week lows in Friday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by about 9 to 5. (19-0)
Today we will discuss Acadia Pharmaceuticals (NASDAQ:ACAD), which has fallen sharply on a CNN report that raised concerns about the Nuplazid’s safety. (210-4)
Silicon Investor Message Boards
This table lists all message boards related to EYEG / Eyegate Pharmaceuticals Inc. on message board site Silicon Investor.
|EYES Second Sight-Eyeglasses for the Blind help them see||EYES Second Sight-Eyeglasses for the Blind help them see||EYES Second Sight-Eyeglasses for the Blind help them see|
as of ET